1. Case of Severe Hypoglycemia Due to False “Normal” Reading

A diabetic patient used a CGM integrated with an insulin pump system. The device displayed a stable glucose level in the normal range, so the patient did not take corrective sugar intake or reduce insulin dosage. Shortly after, the patient suffered severe hypoglycemia leading to unconsciousness and emergency hospitalization.

Legal issues raised:

• Failure to warn: The plaintiff argued the manufacturer did not adequately warn that CGMs may lag behind blood glucose changes by 5–15 minutes.
• Design defect: Allegation that the algorithm smoothing glucose data suppressed rapid drops.
• Negligence: Claim that calibration system allowed drift without clear alerts.

Defense argument:

The manufacturer argued:

• CGMs are adjunct devices, not replacements for fingerstick testing.
• User instructions clearly warn about lag and sensor error.

Outcome pattern:

Such cases often settle, with manufacturers emphasizing proper labeling rather than admitting defect.

2. Case of “Compression Low” False Alarms Leading to Insulin Overdose

A patient using a wearable sensor during sleep experienced repeated “low glucose” alarms. These were later identified as compression lows—false readings caused when pressure on the sensor reduces interstitial fluid flow.

The patient responded by reducing carbohydrate intake and adjusting insulin incorrectly, leading to rebound hyperglycemia and diabetic ketoacidosis (DKA).

Legal claims:

• Defective design: Sensor unable to distinguish real hypoglycemia from pressure interference.
• Failure to provide adequate algorithm filtering.
• Inadequate user instructions about sleeping positions and sensor pressure risks.

Court analysis focus:

Courts in similar medical device cases typically evaluate:

• Whether the risk is inherent and scientifically unavoidable
• Whether alternative safer designs exist

Outcome trend:

Manufacturers often avoid liability if they prove:

• risk is disclosed
• device meets regulatory approval standards

3. Case of Sensor Calibration Error Leading to Wrong Insulin Pump Dosing

A CGM connected to an automated insulin delivery system miscalibrated after a sensor replacement. It repeatedly displayed false high glucose readings, causing the insulin pump to deliver excessive insulin.

The patient experienced severe hypoglycemia requiring ICU admission.

Key legal claims:

• Manufacturing defect: faulty batch of sensors
• Strict liability: product unreasonably dangerous when used as intended
• Breach of warranty: device claimed “high accuracy” within tight margins

Technical dispute:

• Plaintiff experts argued sensor drift exceeded FDA-accepted error limits.
• Defense argued user failed to recalibrate correctly.

Typical legal principle:

In such cases, courts analyze:

• Whether error exceeded “reasonable medical device tolerance”
• Whether user misuse breaks causation chain

4. Case of False High Readings Leading to Chronic Overmedication Injury

A patient relied heavily on CGM readings without confirmatory fingerstick tests. The device consistently showed elevated glucose levels (false hyperglycemia).

Over months, the patient increased insulin dosage, leading to:

• recurrent hypoglycemia episodes
• long-term neurological symptoms

Legal claims:

• Failure to warn about over-reliance
• Defective algorithm smoothing causing systematic bias
• Negligent marketing implying “replacement-level accuracy”

Defense position:

• Instructions clearly state CGM is trend-based, not diagnostic
• User deviated from standard medical guidance

Court reasoning in similar disputes:

Courts often focus on comparative fault, dividing responsibility between:

• manufacturer warning adequacy
• physician instructions
• patient reliance behavior

5. Case of Sensor Adhesive Failure Causing Intermittent False Data

A group of users reported that during physical activity or sweating, the CGM sensor partially detached from skin. This led to intermittent signal loss and erratic glucose spikes on the display.

One user experienced incorrect high glucose alerts during exercise and administered insulin unnecessarily, leading to hypoglycemia.

Legal theories:

• Design defect (adhesive failure under normal use conditions)
• Negligent testing (insufficient real-world sports simulation testing)
• Failure to warn about sweat/heat limitations

Technical focus:

• Whether environmental conditions were “foreseeable use”
• Whether device labeling adequately addressed athletic use

Outcome pattern:

Often resolved through:

• device design modification
• settlement funds for affected users
• updated warnings and packaging instructions

Key Legal Principles Across All CGM False Reading Cases

Across jurisdictions, courts repeatedly evaluate CGM-related injury claims using these core principles:

1. Medical Device “Inherent Limitation”

CGMs measure interstitial fluid, not blood. Courts often accept that:

• some inaccuracy is scientifically unavoidable
• this does not automatically equal defect

2. Adequate Warning Doctrine

If manufacturers clearly warn:

• lag time
• calibration requirements
• environmental interference
  they are less likely to be held liable.

3. User Reliance vs Medical Standard of Care

If a patient ignores:

• confirmatory fingerstick testing
• physician guidance
  courts may reduce liability of manufacturers.

4. Regulatory Compliance Defense

FDA clearance (or equivalent regulatory approval) is often used as evidence that:

• product met baseline safety expectations

Important Reality Note

There are very few publicly reported appellate “case law” decisions specifically titled around CGM false readings. Most legal disputes involving Dexcom, Abbott FreeStyle Libre, or Medtronic devices:

• are settled confidentially
• appear as multidistrict litigation filings
  • or are resolved before full published judgments